Abstract
Objectives: The purpose of paper is to report the mid-term(mean of 24 months) outcome of MV annuloplasty using Carillon coronary sinus (CS) Device therapy in reducing the pulmonary artery systolic pressure(PASP) at PSCC, Saudi Arabia. Background: Carillon CS Device is one of the devices used for treatment of severe functional symptomatic mitral regurgitation in heart failure patients, which is associated with high mortality and difficulty in controlling heart failure symptoms. This study provides a snapshot of the real-world clinical demographic data and outcome on reducing the PASP in a single center using this treatment modality. Methods: A total of 30 patients with severe symptomatic mitral valve regurgitation (MR) underwent Carillon CS Device therapy at Prince Sultan Cardiac Center. All patients were in New York Heart Association functional class III or IV, and 82% of patients had an ejection fraction ≤25%. Results: The Carillon CS Device implant rate was 80%. A total of 1 patient (3%) died within 30 days after the procedure. The mean Intensive care unit and hospital length of stay was 3 days. None of the patients required mitral valve surgery after the MV ring device implant procedure. There was significant drop in the PASP , compared to base line seen (from 60.4±11.9 to 43.0±13.3 (p<0.009)) . 85% of patients had New York Heart Association functional class II or class I, at a mean follow up of 18 months .Six-minutes-walk-test improved 193± 7 m, to 470±5 m (p<0.002). Conclusions: Carillon CS Device therapy used in high risk severe functional symptomatic MR is promising with a low rate of hospital mortality and significant improvement of symptoms and PASP .
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call